Clinical trial
Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With…
NCT00485810 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00485810 |
|---|---|
| Title | Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia |
| Official title | A Study Examining Clinical Therapeutic Dose of Rapid Acting Intra-Muscular Olanzapine in Japanese Agitated Patients With Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine Hydrochloride |
| Enrollment | 31 |
| Start date | Jun 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 13, 2007 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: